Effectiveness of New Analgesic Strategy Compared to the Usal Antalgic Strategy

Overview

Quality of life of adult patients with sickle cell disease is deeply impaired by severe adverse medical events that inadvertently occur throughout their time life. Indeed, patients not presenting a life threatening condition often present to the emergency department with sickle cell disease crisis related pain. Currently, the effectiveness of specific analgesic strategies for treating sickle cell disease crisis related pain are mostly based on acetaminophen and opioid derivates combination along with oxygen delivery. Those strategies are effective but may last up to half an hour to obtain pain relief. This delay mostly depends on the availability of venous access and on individual patient response to treatment. Nitrous oxide is a volatile efficient analgesic therapy that has been repeatedly shown to allow rapid analgesia in the emergency department setting. The investigators hypothesise that a new analgesic strategy (rapid optimized analgesic strategy) including nitrous oxide and nefopam would be as safe and more rapidly effective than current analgesic strategy.

Purpose of the study: The main objective is to evaluate the effectiveness of an optimized combination of analgesic therapies for treating uncomplicated sickle cell disease crisis at initial visit to the emergency room of the Henri Mondor hospital. Secondary objectives: * Total amount of morphine required during the first 4 hours in the hospital emergency. * Overall amount of morphine administered on the duration of patient stay in hospital Henri Mondor. * Side effects of analgesic strategies * Adverse medical events * Length of hospital stay. * 7-day and 1-month follow-up and collection of following data: 1. Total number of sickle cell disease crises 2. Number of subsequent readmission and/or visit to an ED 3. Quality of life (EuroQol EQ-5D, and SF-36) 4. Patient satisfaction: pain treatment satisfaction scale. Study design: prospective monocentric open-label randomized controlled trial Number of patients: 200 Follow up per patient: 1 month, Study enrolment period: 25 months. Contraindications to nefopam administration: hypersensitivity to nefopam, benign prostatic hypertrophy and glaucoma, or history of seizures. * contraindication to morphine administration hypersensitivity to morphine, decompensate respiratory failure, acute head trauma, uncontrolled epilepsy, severe hepatocellular failure, intracranial hypertension, use of buprenorphine or nalbuphine Contraindications to MEOPA administration, intra-cranial hypertension, non cooperative patient (sleepiness; encephalopathy, refusal to participate), pneumothorax, emphysema, pneumoperitoneum, digestive occlusion, pneumomediastinum, air embolism, diving accident , facial trauma, patients who recent administration of an ophthalmic gas (SF6, C3F8, C2F6) \< 3 months). * contraindication to the use of oxygen: no-absolute contraindication no health insurance, adults under tutelage Main criterion: Proportion of patients relieved (pain intensity by simple numerical scale \<4) to 30 minutes of their arrival in the emergency department. Secondary criteria: * amount of morphine administrated within the first 4 hours of presentation to the emergency department * overall amount of morphine administrated during hospital stay * adverse event related with study treatment * adverse medical events during hospitalization * length of stay. * 7-day and 1-month follow-up to collect the following data: 1. Total number of sickle cell disease crises 2. Number of subsequent readmission and/or visit to an ED 3. Quality of life (EuroQol EQ-5D, and SF-36) 4. Patient satisfaction: pain treatment satisfaction scale.